Adipotide for Fat Loss: Dramatic in Monkeys, Never Proven in Humans

Adipotide — also called FTPP (fat-targeted proapoptotic peptide) — is a peptidomimetic that targets prohibitin, a protein expressed on the surface of blood vessels feeding white adipose tissue, and kills those vessels from the inside, causing white fat to shrink and die. In obese rhesus monkeys, a single four-week course produced rapid, substantial weight loss and improved insulin resistance^[2] — results striking enough to generate widespread press coverage and a thriving grey-market trade in the compound. The honest follow-up is less exciting: the same 2011 primate study documented changes in kidney proximal tubule function at the tested doses^[2], no completed human obesity trial has ever been conducted, and adipotide has not advanced through the clinical pipeline. Buying or injecting grey-market adipotide means accepting unknown kidney risk and zero human efficacy evidence — while proven GLP-1 medications exist with thousands of human trial participants behind them. See our peptides hub for context on the broader landscape.

What adipotide is and how it works

Adipotide is the informal name for the peptidomimetic compound CKGGRAKDC-GG-(D)(KLAKLAK)2. It is a fusion of two functional domains: CKGGRAKDC, a peptide sequence isolated by Kolonin et al. in 2004 via in vivo phage display that selectively homes to the vasculature of white adipose tissue^[1]; and (D)(KLAKLAK)2, a pro-apoptotic sequence that disrupts mitochondrial membranes and triggers cell death. The two domains are joined by a GG linker. Alone, CKGGRAKDC can locate and bind to white fat blood vessels. Conjugated to the killing domain, it delivers targeted apoptosis specifically to those vessels.

The molecular target is prohibitin — a multifunctional membrane protein that Kolonin et al. established as a vascular marker of adipose tissue^[1]. Prohibitin is expressed on the luminal surface of endothelial cells in white fat capillaries, making it accessible to injected peptide circulating in the bloodstream. When adipotide binds prohibitin-expressing endothelial cells and triggers apoptosis, the blood supply to a fat depot collapses, the depot loses its nutrient supply, adipocytes die, and white fat mass shrinks. Subsequent work by Staquicini et al. confirmed using direct combinatorial selection in human cancer patients that prohibitin/annexin A2 is specifically expressed in the white adipose tissue vasculature of humans^[3] — a finding that made the translation case seem compelling. Later work confirmed that the adipose homing peptide (AHP, i.e., CKGGRAKDC) selectively accumulates in white adipose tissue in vivo in diet-induced obese rats^[4].

The animal evidence: why the excitement was real

The 2004 Nature Medicine paper by Kolonin et al. was proof of concept in mice^[1]. Obese mice treated with the prohibitin-targeting pro-apoptotic conjugate showed resorption of established white adipose tissue, normalization of metabolism, and obesity reversal — without detectable adverse effects at the doses studied. The results were striking but mouse-to-human translation in obesity research has a poor historical record, so the critical test was a primate study.

That test came in 2011. Barnhart et al. published a Science Translational Medicine study of adipotide in obese Old World monkeys — specifically obese rhesus macaques, which share obesity physiology more closely with humans than rodents do^[2]. Over a four-week treatment period, treated animals showed: rapid weight loss, confirmed by dual-energy X-ray absorptiometry; marked reduction in white adipose tissue on MRI; and improved insulin resistance. These were genuinely impressive findings in a translationally relevant model. The paper concluded that adipotide "may be useful for treating obesity in humans" and described the compound as a "prototype in a new class of candidate drugs."

The kidney signal that stalled development

The Barnhart 2011 monkey study was scientifically important — and it was also where clinical development effectively stalled. The paper reported "predictable and reversible changes in renal proximal tubule function" at experimentally determined optimal doses, observed across three different primate species^[2]. Renal proximal tubule dysfunction is a specific form of kidney damage: the proximal tubule is responsible for reabsorbing glucose, amino acids, electrolytes, and low-molecular-weight proteins from the glomerular filtrate. Damage to it — nephrotoxicity — is a serious safety concern and a common reason that otherwise promising compounds fail in drug development.

The paper characterized the changes as "reversible," which is a meaningful qualifier — it means kidney function recovered after treatment ended. But "reversible at the doses and durations studied in four-week monkey experiments" is not the same as "safe at doses and durations that would be used in a multi-month human obesity treatment." Reversibility in four-week primate studies does not rule out irreversible damage in longer courses or at the doses required for clinically meaningful human weight loss. The nephrotoxicity signal in a primate model is precisely the kind of finding that triggers intense scrutiny from the FDA in IND applications and Phase I dose-escalation design — and no Phase I or Phase II human obesity trial for adipotide has been published or registered.

No completed human obesity trial

Despite the compelling primate data published in 2011, adipotide has not progressed through human clinical trials for obesity. No completed Phase II or Phase III randomized controlled trial of adipotide for obesity has been published in the scientific literature. No published IND (Investigational New Drug) application exists for a human obesity indication. The compound's clinical development stalled — most likely due to a combination of the nephrotoxicity signal in primates, the difficulty of characterizing a safe dose-response for a proapoptotic agent that damages healthy tissue (the vasculature of fat depots), and the practical challenge of obtaining regulatory clearance for a compound with documented kidney effects in non-human primates.

This is the essential fact underlying every claim made about adipotide for human weight loss: there is no human efficacy data. Not insufficient human data — zero completed trials. The dramatic weight loss seen in obese monkeys may or may not translate to humans at doses that do not cause irreversible kidney damage. No one has tested this. The scientific community does not know whether adipotide works in humans, at what dose, or at what kidney cost. Anyone injecting grey-market adipotide is not "trying a promising experimental treatment" — they are self-experimenting with a compound that has a documented kidney toxicity signal and no established human dose.

Why adipotide appears on grey-market sites

The 2011 Barnhart study received significant media attention, and the mechanism — killing fat's blood supply — is viscerally compelling in a way that conventional weight-loss pharmacology is not. Within the "research chemical" and "peptide" grey market, compounds do not need to complete human trials before being sold: they need only a plausible scientific story and a sufficiently interested customer base. Adipotide checks those boxes. Grey-market suppliers sell it labeled "for research use only — not for human consumption," a legal disclaimer that does not protect buyers from the compound's actual biological effects.

Grey-market adipotide carries all the risks of any unregulated injectable compound: unknown identity and purity (no regulatory body verifies that the vial contains what the label says, at the stated dose, without undisclosed impurities); non-sterility (injection-site abscesses, cellulitis, systemic infection); and no established human dose (the dose that caused weight loss in monkeys also caused kidney changes — no one knows what dose, if any, causes weight loss in humans without kidney damage). These risks exist in addition to the compound's intrinsic biology, not instead of it.

Contrast: GLP-1 medications with proven human evidence

The contrast with approved GLP-1 receptor agonists is stark. Semaglutide 2.4 mg (Wegovy) was evaluated in STEP-1, a 68-week double-blind randomized controlled trial of 1,961 adults with overweight or obesity, finding a mean weight loss of approximately 14.9% of body weight versus 2.4% with placebo^[5]. Tirzepatide (Zepbound), a dual GIP/GLP-1 agonist, was evaluated in SURMOUNT-1, a 72-week randomized trial of 2,539 adults, with the 15 mg dose achieving a mean weight loss of approximately 20.9%^[6]. Both compounds have multi-thousand-participant safety databases, long-term follow-up data, known adverse-effect profiles, regulatory approval, physician oversight, and pharmacy-grade manufacturing. They are not perfect medications — nausea, vomiting, and other GI effects are common, and long-term cardiovascular data is still accruing for some formulations — but the comparison with adipotide is not between a "natural" and a "pharmaceutical" treatment. It is between treatments with human evidence and a compound with none. See our companion article for a head-to-head review: Semaglutide vs. Peptides for Weight Loss.